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Abstract: The underlying problem for two of
the three most common patterns of
unexpected hospital deaths (PUHD) is
hypoventilation1. Current methods of postoperative respiratory monitoring give
delayed signals and have a high false
positive rate leading nurses to ignore
alarms. We hypothesize there exists a
combination of low cost sensors which are
capable of providing real time feedback and
alarms regarding obstructive sleep apnea
and ventilatory depression. Such a monitor
would be useful during space travel when
monitoring personnel are limited following
an injury or if astronauts were to be sedated
during extended travel. Methods: Twenty-six
subjects will be recruited to participate in a
study of the effects of Propofol and
Remifentanil. Throughout the day, these
patients will be exposed to varying levels of
both drugs simultaneously via target
controlled infusions. These patients will be
attached to breathing and oxygen monitors
including chest bands, pulse oximeters,
nasal pressure sensors, C02 capnography,
breathing microphones, and thermistors.
The patients are then observed for types of
apnea or ventilatory depression. Results:
The study is currently ongoing however
preliminary analyses of the data indicate
multiple low cost sensors are capable of
detecting breathing as well as obstructive
events and apnea. Conclusion: Using only a
combination of low cost sensors, we can
provide real time respiratory event data to
nurses and practitioners.

INTRODUCTION & BACKGROUND
The underlying problem for two of the three
most common patterns of unexpected
hospital deaths (PUHD) is hypoventilation1.
Type II PUHD (CO2 narcosis) involves a
reduction in respiratory rate and/or tidal
volume, and if supplemental oxygen is
being provided, a pulse oximeter will not
detect the problem until the hypercarbia is
significantly advanced and the patient is
near respiratory arrest. Type III PUHD is
induced by obstructive sleep apnea in the
presence of arousal failure, and is
recognized as a repetitive sequence of
cyclic apneas and self-arousals which
precede the final apnea. A pulse oximeter
alarms with each apneic period and will
likely be interpreted as generating many
false positive alarms.1 The risk of opioidinduced
respiratory
depression
in
postoperative patients is greatest in the first
24 hours after initiation of opioids2, and
opioids are the most commonly used drug
for treating pain in the postoperative
period.3
These problems would be especially
apparent in space travel where monitoring
personnel are limited due to either sedation
of crew members or an injury rendering the
crew short-handed.
Respiratory depression is caused by druginduced inhibition of the breathing control
center of the brain stem. Partial to full
airway obstruction is an anatomic problem
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involving the soft palate, tongue base,
and/or epiglottis, caused by drug-induced
decreases in airway patency and muscle
tone. Sedatives and opioids depress the
response to elevated CO2 (reduced drive to
breathe), worsen arousal, cause airway
obstruction, and change sleep patterns4-8

2
low cost, reliable respiratory depression
monitoring technique that can be integrated
with the signals from the pulse oximeter to
give additional physiologic information about
a patient’s sufficiency of both ventilation and
oxygenation.

In the postoperative period, most adverse
respiratory events occur during the first 24
hours of opioid administration.2 During this
period,
pulse
oximeter
monitoring,
supplemental oxygen, incentive spirometry,
and intermittent nursing observation are the
primary interventions used to fend off
adverse respiratory events. For inpatient
monitoring, pulse oximetry is often
inadequate. On a busy hospital floor, it is
difficult to respond to multiple remote
advisory pulse oximetry alarms. Pulse
oximeter alarms are ignored because they
have a high false-positive alarm rate due to
movement artifact and displacement.9,10
Pulse
oximetry
primarily
monitors
oxygenation instead of ventilation; the SpO2
signal is a delayed indicator for apnea or
hypopnea, particularly when supplemental
oxygen is given. By the time the pulse
oximeter alarms, an apneic patient is
already in danger of hypoxia, brain injury
and death.

Currently, we are exploring the value of
integrating the information from a set of lowcost physiologic monitors that can be
adapted to monitoring patients. In addition
to the red and infrared component signals
that
comprise
the
pulse
oximeter
plethysmography waveform, we intend to
integrate information from motion sensors
on the finger, head, abdomen, chest wall
and bed, temperature, pressure and carbon
dioxide sensors embedded in a nasal
cannula and acoustic respiratory rate via a
microphone on the throat. We will determine
from the tested set the fewest number and
least costly types of sensors that can be
used to accurately identify and quantify
ventilatory
depression
and
airway
obstruction, provide reliable measures of
oxygenation AND ventilation, provide
specific alarms, and avoid artifact. We will
evaluate this multi-sensor set for volunteers
who receive medications to produce
ventilatory depression and/or partial to
complete airway obstruction.

Existing
technologies
may
improve
monitoring of adverse respiratory events in
this setting, but are either costly or difficult
to implement. For example, monitoring
ventilation with capnography is expensive
and it can be problematic to sample the
exhaled gas with a face mask or nasal
cannula
in
non-intubated
patients.11
Acoustic respiratory rate monitoring may be
able to detect airway obstruction, but it is
costly and may not have sufficient sensitivity
to reliably detect apnea events.12 We
suggest that there is an urgent need for a

Our team previously characterized various
effects of sedatives combined with opioids
using drug interaction models. Specifically,
we characterized the interaction of Propofol
and Remifentanil on metrics of airway
obstruction and intolerable ventilatory
depression in volunteers.8 We defined
intolerable ventilatory depression as a
respiratory rate less than 4 breaths per
minute and airway compromise as either
partial (tidal volume less than 3 mL/kg in the
presence of a respiratory effort) or complete
obstruction. Respiratory compromise was
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defined as either intolerable ventilatory
depression or airway obstruction or both.
Using this model, predictions of respiratory
compromise (0 to 100%) can be made for
various dosing schemes of Propofol and
remifentanil.8 (Figure 1). In general, dosing
schemes that led to high concentration of
Propofol were more likely to produce airway
obstruction
and
higher
doses
of
Remifentanil were more likely to produce
intolerable ventilatory depression.

B

C

D

Figure 1: A: Dose of a drug, first as a bolus,
then as a continuous infusion. B: effect site
concentration (Ce) Corresponding to the
given dose and C: Observed effect
(sedation) for a single administered drug.
Time points 1-5 correspond to a likelihood of
effect in D: Effect and corresponding drug
concentrations
resulting
in
stated
probabilities for respiratory
METHODScompromise.

A 20 gauge venous catheter is placed in an
antecubital vein under local anesthesia (0.2
mL of 0.5% lidocaine) for the purpose of
hydration and drug administration. The IV
site is similar in all subjects. A maintenance
infusion of 0.9% sodium chloride is
administered at 1 ml/kg/hour throughout the
study. Continuous infusions of Remifentanil
and Propofol are infused into this peripheral
IV.
Subjects
are
instrumented
with
a
noninvasive blood pressure cuff, ECG
leads, pulse oximeter(s), motion sensors,
respiratory inductance plethysmography
"chest bands", capnography nasal cannula,
nasal gas pressure sensor, nasal thermistor
and an acoustic respiratory rate sensor.
These or similar monitors are placed to
measure respiratory rate, tidal volume, endtidal CO2, SpO2, blood pressure, body
motion and heart rate. Chest and abdominal
wall excursion are measured with the
attached motion sensors and the respiratory
inductance
plethysmography
bands.
Changes in respiration pattern will be
displayed as real-time changes in CO2
waveforms. A processed EEG monitor
and/or a cerebral oximeter are optionally
placed to record data for later analysis. A
motion sensor may also be placed on the
bed. These devices are operational during
the entire study day. Data from devices is
electronically captured and recorded for
later analysis. Continuous variables such as
motion
waveforms,
pulse
oximetry
waveform, capnogram, and nasal airway
pressure are digitized during data collection
periods at 50-1000Hz during data collection
periods at each target effect site
concentration pair. Discrete variables are
recorded every 5 seconds or as soon as
data are available during data collection
periods. Examples of discrete variables
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include heart rate, SpO2, PetCO2, systolic
blood pressure, diastolic blood pressure and
respiratory rate. The tidal volume may be
occasionally measured with a differential
pressure flow sensor attached to an
anesthesia mask or mouthpiece in order to
calibrate
the
respiratory
inductance
plethysmography bands.
Each subject will receive Propofol and
Remifentanil. Similar to previously collected
data from our volunteer laboratory (Kern et
al, 2004), each drug will be administered
using a computer controlled (Stanpump14)
continuous infusion pump (Pump 22;
Harvard Apparatus, Limited, Holliston, MA)
to achieve selected target effect site
concentrations.
The
effect
site
concentration
refers
to
the
drug
concentration at the pharmacologic site of
action. Pharmacokinetic
parameters
published by Minto et al.15 and Schnider et
al.16 will be used for Remifentanil and
Propofol respectively.
We administer Propofol and Remifentanil
pairs in a dose escalation scheme with
small steps in order to creep up to the
desired target effects of respiratory
depression, airway obstruction and both
effects while avoiding overshoot. To
accomplish this, the Propofol is dosed in a
range of 0.75 - 4 mcg/mL in dose escalation
steps of approximately 0.5 mcg/mL.
Remifentanil is dosed in a range of 0.75 to
4.0 ng/mL in escalation steps of
approximately 0.25-0.5 ng/mL. If overshoot
is observed for a given target effect site
concentration pair, the target effect site
concentrations may be lowered so
assessments can be made during the target
effects of respiratory depression or airway
obstruction or both. Once the drug
concentration pair is identified which results
in the target effects for a given subject, the

steady state drug dose will be maintained
for a period of data collection.
RESULTS
While the study is currently ongoing, a
preliminary analysis of the data has
revealed high correlation between certain
respiratory monitors and specific breathing
related ‘states’.
These breathing states are ‘normal’
breathing, complete airway obstruction
(obstructive sleep apnea), partial airway
obstruction (partial obstructive sleep apnea
or snoring), and ventilatory depression (nonobstructive sleep apnea) characterized by a
breathing rate of less than four breaths per
minute. The figure below illustrates the
some of the primary complex breathing
patterns that we are interested in
monitoring. Ventilatory depression was not
included in the figure as it appears in the
form of intermittent ‘normal’ breathing with
occasionally reduced volume.
From this data we can already see multiple
breathing patterns once we combine signals
such as chest or abdomen band excursion
(ventilatory effort) and nasal pressure,
expired C02, or thermistor readings
(ventilatory success). In column A, we see
what we would expect for each of these
signals under normal breathing conditions;
The chest and abdomen are in phase with
each other, the biphasic nasal pressure
signal is synced with ventilatory effort, and
the expired C02 increases at expiration.
Column B of figure 2 illustrates how these
signals change during airway obstruction;
Chest and abdomen bands are out of phase
with each other (paradoxical) while
measures of ventilatory success are zeroed.
Column C shows partial airway obstruction;
the abdomen band becomes biphasic and
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only syncs with the chest during the latter
half of the breath attempt where the
obstruction was partially cleared. The lower
magnitude nasal pressure is one indicator of
the patient’s difficulty passing air.
Figure 3 shows an example of audio data
recorded from a microphone attached to
one side of the subject’s throat. Again we
see the differences between normal
breathing (A) and obstructed breathing (B).

5
In the normal breathing case we see a
generally lower magnitude, lower frequency
sound as the passage of air is relatively
quiet. Each breath has two distinct parts:
inspiration and expiration. During obstructed
breathing we see that the expiration phase
is much lower in magnitude (or nonexistent
in the second breath) because little or no air
is passing. The first phase, however, is
much higher in magnitude and frequency
because the airway is restricted.

Figure 2: Electronic signals collected during different breathing related ‘states’. The signals
shown from top to bottom are: Chest band, abdomen band, nasal pressure, expired co2,
and thermistor. The columns are one breath samples from the breathing states listed at the
top of the figure.
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Figure 3: Audio data from a microphone placed to the side of the subject’s throat. Both
samples contain two breath attempts. Row A is an example of normal, unobstructed breathing.
Row B is an example of partially obstructed breathing in the first breath and completely
obstructed breathing in the second.
CONCLUSION
A low cost, accurate, and minimally sized
respiratory monitor would be useful during
space travel when personnel are limited
following an injury/emergency procedure or
if astronauts were to be sedated during
extended voyages.
Overall, preliminary analysis of the signals
has been successful in proving that within
individual patients, low cost signals exhibit
discernible patterns during obstructive
apnea, partial airway obstruction, and
ventilatory depression.
Unfortunately, the data set is slightly too
small at the moment to draw statistically
meaningful conclusions about the amount of
patient to patient variation in signal shape.
Potential variation in signal shape must be
accounted for in any algorithm which
attempts to identify breathing patterns and
adverse respiratory events in a population
of patients.

As we collect more data, we hope to prove
that the data patterns we have thus far
identified persist through patients of variable
age, gender, size, weight, and any other
potentially confounding factors.
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